Navigation Links
Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
Date:5/4/2010

TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.  Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 in New Orleans, Louisiana.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO )

The study was a randomized, double-blind, placebo controlled trial conducted at thirteen centers in the United States in patients with genotype 1 chronic hepatitis C, 35% of whom had advanced stage 3 or 4 fibrosis.  One-hundred and twelve patients were randomized to receive either nitazoxanide (500 mg twice daily) plus peginterferon alfa-2a (Pegasys®, F. Hoffman LaRoche) and ribavirin (Copegus®, F. Hoffman LaRoche) (n=75) or placebo plus Pegasys® and Copegus® (n=37).  The primary endpoint of the study was sustained virologic response (SVR, undetectable HCV RNA 24 weeks after the end of treatment).  SVR occurred in 44% of patients treated with nitazoxanide plus standard therapy for 48 weeks versus 32% of patients treated with placebo plus standard therapy. SVR rates were consistently higher in subsets of patients with high baseline viral load (41% vs. 29%) and in African Americans (38% vs. 20%).  Safety analyse
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
3. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
5. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
6. Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... company that develops and commercializes proprietary technologies and products ... operational results for the fiscal first quarter ended December ... in Canadian dollars (CAD), unless otherwise stated. ... new business from our existing customers and add to ...
(Date:2/26/2015)... 2015 Protiviti ( www.protiviti.com ), a global ... Governance Portal , designed to increase the efficiency ... tasks across multiple business units and projects. The Governance ... better align their controls with the COSO ( Committee ... In response to client feedback, Protiviti has also included ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... SHANGHAI, Oct. 15 /PRNewswire-Asia/ -- ... China, announced today that,Mr. Charles D. Maher has been ... , Prior to joining Sundia, ... Marketing of Azopharma Product Development Group, a CRO company ...
... DENVER, Oct. 15 Global Med Technologies®, Inc. ... GLOB), an international healthcare information technology company, today ... EdgeLab Laboratory Information Management Software (marketed as "Labo ... University Hospital of Reims. Financial terms of ...
... ... recent unpublished study indicated that receiving earlier seasonal flu shot can double ... an investigation by the World Health Organization and delays in the flu ... people,s growing concern about the safety and efficacy of all flu shots ...
Cached Biology Technology:Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing 2Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France 2Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France 3FluStop natural flu remedy sales increase 700% with confusion about new flu shot study and H1N1 2
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... Sex may in fact be one of the secrets to ... fruit flies suggests a new University of Michigan study that ... flies that perceived sexual pheromones of their female counterparts without ... resistance to starvation and more stress. The sexually frustrated flies lived ...
... are paving the way for fishing fleets to reel in ... profits, according to University of British Columbia researchers. In ... ONE , researchers from UBC,s Fisheries Centre analyzed access agreements ... the South Pacific. They found that EU governments pay 75 ...
... NY (November 27, 2013) An international team of scientists, including ... key metabolic enzyme that common malaria parasites require for survival ... the possibility of a new approach to combating malaria, one ... in the online edition of the journal Nature . ...
Cached Biology News:Fruit flies with better sex lives live longer 2Study finds new vulnerability in malaria parasite 2
Extra Large bottle for hybridization 300 x 70mm...
... Microtube Rotor is TWO ROTORS in ONE! ... You can spin both 1.5 - ... polypropylene rotor design provides excellent chemical resistance ... rotors are fully compatible with common decontamination ...
... offers lower consumption of reagents and ... The Multidrop 384 is an automated ... microvolume dispensing into 384- and 96-well ... It can easily switch from 96- ...
...
Biology Products: